Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04102761 · ClinicalTrials.gov registry record · NA
The Use of PRP and BMC in Patients With Internal Disc Disruption Multicenter Prospective Randomized Controlled Trial in Patients With Internal Disc Disruption
A NA study of Internal Disc Disruption, sponsored by Annu Navani.
- Completed
- Registry status
- NA
- Development phase
- 45
- Enrollment target
- 4
- Study locations
NCT04102761: Completed NA study of Internal Disc Disruption, sponsored by Annu Navani.
NCT04102761 is a NA study of Internal Disc Disruption that has completed, run by Annu Navani. The registered enrollment target is 45 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). The trial reports 4 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04102761, a NA study of Internal Disc Disruption, has completed, sponsored by Annu Navani.
- COMPLETED
- Registry status
- NA
- Development phase
- 45 participants
- Enrollment target
- 4
- Study locations
Study Summary
The condition being studied is chronic low back or leg pain in patients with internal disc disruption (IDD). The intervention to be studied is the intradiscal delivery of autologous Platelet Rich Plasma (PRP) or bone marrow concentrate (BMC) into the nucleus pulposus of the disrupted disc(s).
Primary Outcome
Pre and post op discs will be examined and compared for worsening pathology.
Conditions Studied
Interventions
- PROCEDURE Intradiscal PRP & BMC Injections
Study Locations (4)
California
- Alex Hames - Campbell
- The Orthohealing Center - Los Angeles
Texas
- Texas Spine and Joint Hospital - Tyler
Utah
- Nexus Pain Care - Provo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2018-03-27 |
| Est. Completion | 2020-12-31 |
| Phase | NA |
What the finished NCT04102761 record still lists
NCT04102761 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Internal Disc Disruption appearing as the primary indexed condition, and to 1 intervention - of which Intradiscal PRP & BMC Injections is the first listed.
NCT04102761 reports a single indexed study location in California, Texas, Utah.
Frequently Asked Questions
What is clinical trial NCT04102761 about?
NCT04102761 is a clinical study titled "The Use of PRP and BMC in Patients With Internal Disc Disruption Multicenter Prospective Randomized Controlled Trial in Patients With Internal Disc Disruption". The condition being studied is chronic low back or leg pain in patients with internal disc disruption (IDD). The intervention to be studied is the intradiscal delivery of autologous Platelet Rich Plasma (PRP) or bone marrow concentrate (BMC) into the nucleus pulposus of the disrupted disc(s).
What is the current status of trial NCT04102761?
This trial is currently completed. It is a NA study. The enrollment target is 45 participants. The study started on 2018-03-27. Estimated completion is 2020-12-31.
What conditions does trial NCT04102761 study?
This clinical trial studies the following conditions: Internal Disc Disruption.
What interventions are being tested in trial NCT04102761?
The interventions under investigation include: Intradiscal PRP & BMC Injections (PROCEDURE).
Who is sponsoring clinical trial NCT04102761?
This trial is sponsored by Annu Navani, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04102761 being conducted?
This trial has 4 study locations across California, Texas, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04102761's enrollment target sits among peer trials
45 1411th of 2000 higher than 578 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI